Daniel T. Kajunski

Dan is a corporate and securities attorney whose practice spans the full gamut of corporate law. He has advised clients for over two decades in public and private equity and debt financings, securities law matters, mergers and acquisitions, and strategic advice on a broad range of other corporate matters. He capably counsels public and private companies with offerings, compliance, and securities questions and leads buyers and sellers throughout the transaction process. Dan represents life sciences companies as well as clients in other technology fields, financial services, and professional services firms.

Dan’s practice focuses primarily on venture finance, securities law and offerings, mergers and acquisitions, and general business and corporate law, primarily for life sciences and technology companies.

VCs, strategic investors, and issuers rely on Dan’s extensive experience in private fund raising, including equity and debt financings. Public companies also turn to him in connection with public and private offerings and their securities law and compliance needs. In addition, both buyers and sellers engage Dan to counsel them in complicated mergers and acquisitions. Dan also regularly advises both private and public companies at various stages of development on general corporate matters.

Prior to joining the firm, Dan served as a law clerk to the justices of the Superior Court of Massachusetts. While in law school, he served as a staff author and comment editor for the Suffolk University Law Review.

Offerings for Public Companies

Represented Vertex Pharmaceuticals (Nasdaq: VRTX) in over $2.0 billion in equity and debt offerings since 2006
Represented ImmunoGen (Nasdaq: IMGN) in approximately $350 million in equity offerings since 2008
Represented Amedica (Nasdaq: AMDA) in its IPO
Represented the underwriters in the IPO of Calithera Biosciences (Nasdaq: CALA)
Represented the underwriters in the IPO of American Depositary Shares of GW Pharmaceuticals (Nasdaq: GWPH) and two additional follow-on offerings

Venture Capital & Strategic Financings

Represented a public technology company in the semiconductor and life sciences industry (Nasdaq) in multiple strategic investments
Represented a public medical device company (NYSE) in multiple strategic investments
Represented Clarus Ventures in its investments in Ophthotech (Nasdaq: OPHT), VBI Vaccines (Nasdaq: VBIV), TyRx Pharma, and Link Medicine
Represented a public biotechnology company (Nasdaq) in its strategic equity investment in a private biotechnology company
Represented Style Me Pretty in its strategic investment from AOL (NYSE: AOL)
Represented Synchroneuron in multiple equity financings
Represented TransMolecular in multiple equity and debt financings
Represented Ion Torrent Systems in multiple equity financings
Represented I-Pulse in multiple equity financings
Represented TransForm Pharmaceuticals in multiple equity financings
Represented Hemera Biosciences in its Series A financing

Mergers & Acquisitions

Represented Brooks Automation (Nasdaq: BRKS) in its purchase of BioStorage Technologies
Represented a public biotechnology company (Nasdaq) in its entering into a merger option to acquire a private biotechnology company
Represented Clarus Ventures in the reverse merger of VBI Vaccines (Nasdaq: VBIV) with Paulson Capital
Represented Orchid BioSciences (Nasdaq: ORCH) in its sale to Laboratory Corporation of America (NYSE: LH)
Represented QIAGEN (Nasdaq: QGEN) in its purchase of SA Biosciences
Represented TransMolecular in its sale to Morphotek (a subsidiary of Eisai Co. (Tokyo Stock Exchange))
Represented Auspice in its sale to the ARRIS Group (Nasdaq: ARRS)
Represented EPIX Pharmaceuticals (Nasdaq: EPIX) in its merger with Predix Pharmaceuticals
Represented TransForm Pharmaceuticals in its sale to Johnson & Johnson (NYSE: JNJ)
Represented FastClick (Nasdaq: FSTC) in its sale to ValueClick (Nasdaq: VCLK)

Read less

SEC Adopts Pay Versus Performance Compensation Disclosure Requirements

September 26, 2022 | Advisory | By Xandy Walsh, Anne Bruno, Daniel T. Kajunski

July 26, 2022 | Advisory | By Daniel T. Kajunski

January 18, 2022 | Advisory | By Megan Gates, John Condon, Anne Bruno, Melanie Ruthrauff Levy, Daniel T. Kajunski, Cynthia Larose, Breton Leone-Quick, Page R. Hubben

Read about key regulatory and other developments, including board diversity and other ESG matters, which public companies need to consider as they prepare for their fiscal year-end SEC filings and 2022 annual shareholder meetings.

May 27, 2021 | Advisory | By Daniel T. Kajunski

This Mintz advisory reviews amendments approved by the SEC in April 2021 to the NYSE’s rule governing the review and evaluation of related party transactions.

May 26, 2021 | Advisory | By Daniel T. Kajunski

This Mintz advisory reviews amendments approved by the SEC in April 2021 to the NYSE’s shareholder approval rules for related party issuances and the issuance of 20% or more of a company’s stock.

February 5, 2021 | Alert | By Daniel T. Kajunski, Amanda Mei

This advisory summarizes SEC amendments, effective February 10, 202, to MD&A and other financial disclosure requirements and provides a chart highlighting the amended rules.

January 21, 2021 | Advisory | By Megan Gates, John Condon, Daniel T. Kajunski, Anne Bruno

Read about regulatory and other developments public companies need to consider as they prepare for fiscal year-end Securities and Exchange Commission filings and 2021 annual shareholder meetings.

December 3, 2020 | Advisory | By Daniel T. Kajunski

Read about Nasdaq’s proposed new listing rules, which would generally require U.S. listing companies to appoint a certain number of diverse directors.

November 19, 2020 | Alert | By Daniel T. Kajunski

This alert discusses the SEC’s November 17, 2020 adoption of rule amendments that allow the use of electronic signatures in some circumstances — a step that will streamline filing procedures for public companies.